On April 21st, Keyuan Pharmaceutical (301281. SZ) released a restructuring report, stating that the company plans to issue shares to 38 counterparties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd., to purchase its 99.42% stake in Hongjitang. At the same time, the company plans to issue shares to no more than 35 specific targets to raise matching funds, with a total fundraising amount not exceeding 700 million yuan. The main business of the target company is the R&D, production and sales of traditional Chinese patent medicines and simple preparations, health products, muscone and other products. After the completion of this transaction, the main business of the listed company will be extended to traditional Chinese patent medicines and simple preparations, health products, muscone and other fields.
Scan code to share